CDC gives go-ahead for maskless gatherings of the fully vaccinated

The Centers for Disease Control and Prevention has updated its guidance on COVID-19 vaccinations, clearing the way for fully vaccinated individuals to gather with other vaccinated people indoors without masks or social distancing. 

The CDC considers individuals to be fully vaccinated about two weeks after receiving their complete inoculation. So far, there are three available vaccines in the U.S., including the Pfizer-BioNTech and Moderna vaccines, which require two doses, and the Johnson & Johnson vaccine, which requires just one.

“We know that people want to get vaccinated so they can get back to doing the things they enjoy with the people they love,” CDC Director Rochelle Walensky said in a statement. “There are some activities that fully vaccinated people can begin to resume now in the privacy of their own homes. Everyone—even those who are vaccinated—should continue with all mitigation strategies when in public settings.”

Already, the U.S. has administered more than 90 million vaccines, according to the CDC. There are nearly 29 million cases of Covid-19 in the U.S., resulting in more than 522,000 total deaths. President Biden previously advised that the U.S. will have enough vaccine supply for all Americans by the end of May 2021.

While vaccinated groups will be able to resume some activities with other vaccinated people, the CDC still urged Americans to take precautions, including wearing a facemask around others and continuing to practice social distancing.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.